For patients with high-grade carotid stenosis without recent symptoms, the addition of stenting is associated with a reduced ...
MedPage Today on MSN
Bispecific Trial in Myeloma Sparks Talks of 'Functional Cure'
Combination reduced risk of progression or death by 83% compared to standard triplet ...
York school officials are weighing reorganization plans that could cost between $39 million and $88.3 million. Here are the ...
The addition of ianalumab to eltrombopag significantly improved outcomes for patients with pretreated primary immune ...
The addition of epcoritamab to standard therapy significantly improved PFS for patients with relapsed or refractory ...
The Pennsylvania Education Department released the latest round of PSSA and Keystone test results for 2025. Lehigh Valley schools placed near the top and close to the bottom of the lists for math and ...
MLB Insiders praised the Pittsburgh Pirates in their recent trade with the Boston Red Sox.
The EPCORE FL-1 trial evaluated epcoritamb plus lenalidomide and rituximab versus plus lenalidomide and rituximab for efficacy and safety in patients with relapsed/refractory follicular lymphoma in ...
"We have a lot of good holdings and trades, and good credit selection in other sectors that in the short term have been ...
SupportApp 3.0 arrives with a new macOS 26 design, enhanced accessibility features, and a powerful Configurator Mode that ...
Insurance firm triples Manchester footprint with one of the city’s largest office lettings this year
An insurance agency has completed one of the largest office lettings in Manchester this year, taking a further 35,000 sq ft at a landmark building in the city.
News Medical on MSN
New trial shows major survival gains with epcoritamab added to standard R2 therapy
In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results